Stock News
Categories
- All
- Editor's Picks
- Stock Analysis
- Stock Market News
- Q&A with Gurus
- Gurus' Stock Picks
- Insider Transaction
- Earning Reports
- CEO Shareholder Letters
- Press Release
- Crypto Press Release
- Earnings Call Transcripts
- Instant Alerts
- Podcast
Industries
- Aerospace & Defense
- Agriculture
- Asset Management
- Banks
- Beverages - Alcoholic
- Beverages - Non-Alcoholic
- Biotechnology
- Building Materials
- Business Services
- Capital Markets
- Chemicals
- Conglomerates
- Construction
- Consumer Packaged Goods
- Credit Services
- Diversified Financial Services
- Drug Manufacturers
- Education
- Farm & Heavy Construction Machinery
- Forest Products
- Furnishings, Fixtures & Appliances
- Hardware
- Healthcare Plans
- Healthcare Providers & Services
- Homebuilding & Construction
- Industrial Distribution
- Industrial Products
- Insurance
- Interactive Media
- Manufacturing - Apparel & Accessories
- Media - Diversified
- Medical Devices & Instruments
- Medical Diagnostics & Research
- Medical Distribution
- Metals & Mining
- Oil & Gas
- Other Energy Sources
- Packaging & Containers
- Personal Services
- Real Estate
- REITs
- Restaurants
- Retail - Cyclical
- Retail - Defensive
- Semiconductors
- Software
- Steel
- Telecommunication Services
- Tobacco Products
- Transportation
- Travel & Leisure
- Utilities - Independent Power Producers
- Utilities - Regulated
- Vehicles & Parts
- Waste Management
Medical Devices & Instruments
Edwards Lifesciences Corp (EW) Q4 2024 Earnings Call Highlights: Strong Full-Year Growth and Strategic Focus on Structural Heart Technologies
Edwards Lifesciences Corp (EW) reports robust 9% sales growth for 2024, driven by TMTT segment and strategic acquisitions, despite regional challenges and TAVR growth pressures. Feb 12, 2025
Drug Manufacturers
Gilead Sciences Inc (GILD) Q4 2024 Earnings Call Highlights: Strong Growth in HIV and Oncology Segments
Gilead Sciences Inc (GILD) reports robust sales growth, driven by HIV and oncology advancements, despite challenges from Veklury sales decline and Medicare reforms. Feb 12, 2025